Vivek Subbiah: The development of immunotherapy in MSI-H and D-MMR cancers by Thierry Andre et al.
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn about a recent paper by Thierry Andre et al. published in NEJM:
“Wow! The development of immunotherapy in MSI-H and D-MMR cancers clearly demonstrates the power of biomarker driven drug development.
The combination of nivolumab and ipilimumab in patients with Microsatellite-Instability–High metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy!”
“Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer”
Authors: Thierry Andre, Elena Elez, Eric Van Cutsem, Sandzhar Abdullaev, Sara Lonardi et al.
More posts featuring Vivek Subbiah.
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023